drugset
drugset / Trial / NCT03602261

Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI

NCT03602261 ↗

Phase 2 Terminated 44 enrolled OPKO Health, Inc.
RandomizedParallel-groupSingle-blindTreatment

Summary

Safety, Efficacy, PK and PD of CTAP101 (calcifediol) ER Capsules for SHPT in HD Patients VDI

Timeline

Start
2018-07-09
Primary completion
2021-02-24
Completion
2021-02-24

Outcome

Outcome not reported

Stopped: “Cohort 1 completed and cohort 2 terminated prior to initiation per company decision”

Drugs

EvaluationDrugModalityDoseRoute
Comparator Calcifediol Unknown 900 ug Oral

Indications

end stage renal failure secondary hyperparathyroidism of renal origin vitamin D deficiency